June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Cell-injection Therapy Using Rho Kinase Inhibitor in a Corneal Endothelial Dysfunction Rabbit Model
Author Affiliations & Notes
  • Junji Kitano
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Naoki Okumura
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • EunDuck Kay
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Morio Ueno
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Junji Hamuro
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Noriko Koizumi
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Footnotes
    Commercial Relationships Junji Kitano, None; Naoki Okumura, None; EunDuck Kay, None; Morio Ueno, Senju Pharmaceutical Co (P), Santen Pharmaceutical Co (P); Junji Hamuro, None; Shigeru Kinoshita, Senju Pharmaceutical Co (P), Santen Pharmaceutical Co (P), Otsuka Pharmaceutical Co (C), Alcon (R), AMO (R), HOYA (R); Noriko Koizumi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1692. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Junji Kitano, Naoki Okumura, EunDuck Kay, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Noriko Koizumi; Cell-injection Therapy Using Rho Kinase Inhibitor in a Corneal Endothelial Dysfunction Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1692.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate feasibility of corneal endothelial reconstruction by a cell-injection therapy using cultivated rabbit corneal endothelial cells (RCECs) in a corneal endothelial dysfunction rabbit model and to determine the optimum cell numbers for the cell-injection therapy.

Methods: Rabbit corneal endothelium was denuded by intensive mechanical scraping. Cultivated RCECs in the presence of 100μM of Rho kinase (ROCK) inhibitor, Y-27632, were injected into the anterior chamber of the host animals at three concentrations (2x105 cells, 5.0x105cells, or 1.0x106cells). The eyes of each animal were kept in the face-down position for 3 hours. Slit-lamp examinations, corneal thickness- and intraocular pressure- measurements, and immunohistochemical analysis were performed for up to 14 days.

Results: All eyes received cell-injection therapy showed improved corneal clarity; corneal clarity and corneal thickness recovered the fastest rate in the host animals that received cultivated RCECs at 1.0x106cell numbers. In all animal groups, corneal endothelium demonstrated the characteristic contact-inhibited monolayer with polygonal cells that express the functional endothelial phenotypic proteins, ZO-1 and Na+/K+-ATPase. When the endothelial cell density of the host animals was measured, the animal that received a cell injection at 1.0x106 cells demonstrated significant high cell density with 3296.6±365.1 cells/mm2, while the other two animal groups showed 1432.0±200.8 cells/mm2 (injected cell numbers: 2.0x105) and 2252.2±204.6 cells/mm2 (injected cell numbers: 5.0x105 cells). None of the eyes of the experimental animals showed elevated intraocular pressure or immunological rejection.

Conclusions: The findings provide evidence that the cell-injection therapy using appropriate cell numbers with ROCK inhibitor enables corneal endothelial regeneration by tissue engineering technique and may be a useful clinical alternative for corneal transplantation.

Keywords: 481 cornea: endothelium • 480 cornea: basic science • 687 regeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×